Zealand Pharma may be gearing up for a high-stakes year of obesity readouts, but the Danish biopharma thinks the brain could hold the key to the company’s long-term success. | Zealand Pharma may be ...

After securing Medicare reimbursement for its pacemaker-like heart failure (HF) implant, Impulse Dynamics has raised more ...

After a year marked by dramatic ups and downs, William Blair analysts say 2026 could carry forward the industry’s current ...

Arcus will now refocus its efforts outside of TIGIT, specifically on its asset casdatifan, an HIF-2a inhibitor once backed by Gilead, as well as its earlier stage small-molecule inflammatory and ...

Applied’s lead candidate is a selective aldose reductase inhibitor called govorestat, an asset that failed to hit primary endpoints in late-stage trials for a progressive neuromuscular disease called ...

Welcome to this week's Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the ...

After receiving word late last month that the FDA would not be issuing a 510(k) clearance to its cable-free electrocardiogram ...

Lumos Labs has obtained a clearance from the FDA for its popular Lumosity brain training platform, greenlighting a version of ...

Rezolute’s stock has plunged 87% after the company’s rare disease drug flunked the final clinical test ahead of a planned ...

Eli Lilly has surpassed analysts’ highest hopes for the efficacy of retatrutide, linking the triple agonist to 28.7% weight ...

Moderna has tapped Swedish long-acting drug formulation company Nanexa to improve the delivery of up to five injectable ...

The FDA has approved its first at-home, nondrug therapy for depression, with a wearable brain stimulation headset developed by Flow Neuroscience.  | The FDA issued a green light that covers the ...